Why Illumina (ILMN) Could Beat Earnings Estimates Again
Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Strategic Buy Lights Up This Biotech Stock: Time to Invest?
Life sciences company Illumina Inc. NASDAQ: ILMN stock surged over 10% following its announcement of the acquisition of Fluent Biosciences. This comes after its divestiture and spin-off of GRAIL, L...
Illumina to take $1.47 bln goodwill impairment charge related to Grail in Q2
Illumina said on Thursday it will take a goodwill impairment charge of $1.47 billion in the second quarter related to the recently spun-off Grail Inc.
Illumina Completes Spin-Off Of GRAIL
On June 25, 2024, Illumina, Inc. (NASDAQ: ILMN, $208.92, Market Capitalization: $18.51 billion) announced the completion of the tax free spin-off of GRAIL, Inc. (NASDAQ: GRAL, $36.84, Market Capita...
Illumina To Spin-Off GRAIL Unit On June 24
On June 3, 2024, Illumina's (NASDAQ: ILMN, $109.82, Market Capitalization: $17.5 billion) board of directors approved the spin-off of its wholly owned subsidiary GRAIL, Inc. and shared the details ...
Illumina DRAGEN v4.3 powers most comprehensive, accurate genome with industry-leading innovations
Latest version includes a prebuilt pangenome capturing more genetic diversity, reducing ancestry bias, and improving accuracy SAN DIEGO , June 11, 2024 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN),...
Up Nearly 15% In A Week Will Illumina Stock Continue To See Higher Levels?
Illumina stock (NASDAQ: ILMN) saw a 7% rise on Thursday, June 6, faring better than its peer — Mettler-Toledo stock – down 1%. The rise in ILMN stock can primarily be attributed to the company's de...
Illumina launches latest chemistry across most popular mid-throughput sequencers, enabling higher quality and greater speed for customers at lower ...
SAN DIEGO , June 4, 2024 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced that it has completed integration of its latest chem...
Illumina drives genomic testing as standard of care in oncology through collaborative research presented at ASCO
Studies presented represent key focus areas, including building evidence for clinical utility of comprehensive genomic profiling; overcoming market access barriers, and progressing the whole-genome...
Integrated Biosciences Joins Illumina Ventures Labs to Design Novel Therapeutics Targeting the Transcriptome
SAN CARLOS, Calif.--(BUSINESS WIRE)-- #age--Integrated Biosciences, a biotechnology company pioneering the use of synthetic biology and machine learning to develop next-generation therapeutics for ...
Illumina (ILMN) Q1 Earnings Beat, Adjusted Operating Loss Widens
Illumina (ILMN) surpasses expectations in the first quarter in a challenging global macroeconomic environment.
Illumina (ILMN) Reports Q1 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Illumina (ILMN) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Str...
Illumina reaffirms annual revenue forecast over continued sluggish demand
Illumina reiterated its 2024 revenue forecast on Thursday, expecting continued weak demand from its customers such as medical research labs and hospitals.
Gear Up for Illumina (ILMN) Q1 Earnings: Wall Street Estimates for Key Metrics
Evaluate the expected performance of Illumina (ILMN) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metric...
Can Illumina (ILMN) Keep the Earnings Surprise Streak Alive?
Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Related Companies